Literature DB >> 17424244

Immunotherapy of equine cutaneous lymphosarcome using low dose cyclophosphamide and autologous tumor cells infected with vaccinea virus.

R D Gollagher, B Ziola, B J Chelack, D M Haines.   

Abstract

Entities:  

Year:  1993        PMID: 17424244      PMCID: PMC1686569     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


× No keyword cloud information.
  5 in total

1.  Immunotherapy of the rat 13762SC mammary adenocarcinoma by vaccinia virus augmentation of tumor immunity.

Authors:  T P Archer; P Bretscher; B Ziola
Journal:  Clin Exp Metastasis       Date:  1990 Nov-Dec       Impact factor: 5.150

2.  Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide.

Authors:  D S Hoon; L J Foshag; A S Nizze; R Bohman; D L Morton
Journal:  Cancer Res       Date:  1990-09-01       Impact factor: 12.701

3.  Modulation of the immune system in the mouse. 1. Drug administration prior to antigen sensitization.

Authors:  J Cottney; J Bruin; A J Lewis
Journal:  Agents Actions       Date:  1980-09

4.  Active immunotherapy of human melanoma exploiting the immunopotentiating effects of cyclophosphamide.

Authors:  D Berd; M J Mastrangelo
Journal:  Cancer Invest       Date:  1988       Impact factor: 2.176

5.  Attempted reconstitution of a foal with primary severe combined immunodeficiency.

Authors:  T M Campbell; M J Studdert; W M Ellis; C M Paton
Journal:  Equine Vet J       Date:  1983-07       Impact factor: 2.888

  5 in total
  1 in total

1.  Use of lomustine (CCNU) in a case of cutaneous equine lymphoma.

Authors:  Aimie J Doyle; Valerie S MacDonald; Andrea Bourque
Journal:  Can Vet J       Date:  2013-12       Impact factor: 1.008

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.